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In the PLUMMB trial first
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received radiation therapy during ICB appear to have prolonged survival. The
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We suggest caution when
using large dose per fraction
in the pelvis in combination
with immunotherapy.able 1 Toxicities recorded in the firs
atient number Disease stage
01 T3N1M1
02 T2N0M1
03 T2N1M1a
04 T2bN0M0
05 T3bN0M1
* Common terminology criteria for advers
y Dose-limiting toxicity (DLT) window ex
z Denotes toxicity judged to be related to
x Relationship to treatment uncertain.which were attributable to therapy. One patient experienced a grade 4 rectal perfo-
ration. In view of these findings, the trial has been paused and the protocol will be
amended to reduce radiation therapy dose per fraction. The authors advise caution
to those combining radiation therapy and ICB, particularly when radiation therapy
is given at high dose per fraction for pelvic tumours. The PLUMMB trial met the
protocol-defined definition of dose-limiting toxicity and will be amended to reduce
radiation therapy dose.  2018 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
There is currently significant interest in the potential ben-
efits of combining radiation and immune checkpoint
blockade (ICB) to stimulate both regional and distant
abscopal immune responses (1). In melanoma (2) and lung
cancer (3), patients who have received radiation therapy
during ICB appear to have prolonged survival. A number of
ongoing clinical trials are addressing the role of radiation-
ICB combinations, particularly in clinical settings in which
ICB has been shown to prolong survival as monotherapy.
The PLUMMB (Pembrolizumab in Muscle-invasive/
Metastatic Bladder cancer) study (NCT02560636) is a
phase 1 dose-escalation study in which pembrolizumab is
added to weekly hypofractionated bladder radiation
therapy in patients with localised disease who are too
frail for daily radiation therapy (4) or who have signifi-
cant local symptoms in the context of metastatic disease.
This radiation therapy regimen is used as standard for
this group in PLUMMB. The study employs a standard
phase 1 3 þ 3 design, with dose-escalation of pem-
brolizumab from 100 mg to 200 mg (total dose) in the
absence of dose-limiting toxicity (DLT) during the acutet 5 patients
Maximum CTCAE* tox
during DLT periody
G2 anaemiaz
G2 fatiguez
G2 pain
G3 urinary tract/bladder
infection
G3 haematuria
G3 cystitis (non-infectiv
G2 urinary urgency
G2 urinary incontinence
G3 urinary painz
G3 fatiguez
e events.
tends from first pembrolizumab i
trial treatment.phase after radiation therapy. Pembrolizumab was started
before radiation therapy in line with preclinical evidence
suggesting synergy occurs when ICB is given before or
during radiation therapy (1, 5).
Methods and Materials
Between September 2016 and July 2017, 5 patients were
treated in cohort 1. Eligible patients had histologically
confirmed, muscle-invasive bladder cancer which was
either metastatic (4 patients) or localised in a patient too
frail for daily treatment (1 patient). Eligible patients had
performance status 0-1, had measurable disease by
RECIST v 1.1 or cystoscopy and were permitted to have
received previous platinum-based chemotherapy in the
metastatic setting. Pembrolizumab was delivered at a
dose of 100 mg starting 2 weeks before radiation therapy
commenced, and thereafter was given at a dose of
100 mg 3-weekly. Radiation therapy was delivered ac-
cording to standard protocols, using the ‘plan-of-the-day’
approach, to a dose of 36 Gy in 6 weekly fractions (4).
This approach uses 3 PTV expansions (small, medium
and large) to account for variation in bladder size on theicity
DLT
Significant events other than
DLT
No G3 renal haematoma (post-
stent)
G3 urinary tract infection
Progressive disease
No (see text) Progressive disease
e)z Yes G4 bowel perforation
G3 peripheral oedema (legs)
No n/a
Yes G3 atrio-ventricular blockx
nfusion to 11 weeks post-completion of radiation therapy.
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being selected by the treating radiographers at the time of
each fraction (6). Acute toxicity was assessed weekly
during radiation therapy and, thereafter, 3-weekly using
the common terminology criteria for adverse events
(CTCAE) version 4. Pembrolizumab was scheduled to be
continued until progression, or for 12 months in the
setting of localised disease. The protocol stated that
maximal tolerated dose (MTD) would be declared if 2 or
more patients in the first 6-patient cohort experienced
dose-limiting toxicity (DLT), defined as any grade 4
toxicity, any grade 3 non-haematological toxicity likely
related to treatment within 11 weeks of completing ra-
diation therapy, or radiation therapy interruption for
>5 days.Results
The first cohort of the trial was stopped early after
recording DLT events in 2 of the first 5 patients (Table 1).
All patients completed 6 fractions of radiation therapy. No
patients experienced significant immune-related side
effects.
Patients 003 and 005 had protocol-defined DLT events
judged to be related to treatment. In both cases, symptoms
of bladder irritation (cystitis or pain) were severe. Addi-
tionally, patient 002 had recurrent problems with haema-
turia (the initial indication for palliative radiation therapy)
and urinary sepsis, and patient 1 had urinary obstruction.
The authors cannot rule out some contribution from trial
treatment. Patients 001 and 004 also experienced urinary
symptoms, but at a lower grade. The safety review com-
mittee was convened, per protocol, and the trial has been
suspended at the current doses.Discussion
A number of investigators have reported retrospective
studies showing that combinations of pembrolizumab and
(mostly) palliative radiation therapy are tolerable (2, 3, 7).
Interestingly, however, careful review highlights a non-
significant trend to increased in-field toxicities in these
studies.
With such small numbers in the PLUMMB trial, it may
be that we have made a type I error in suspending
recruitment. The dose of radiation therapy used in this trial
is standard in many UK centres, and has been used as
standard for decades, with good results (4, 5). Our previous
experience has shown that a proportion of patients (around
9%) will experience emergent grade 3 toxicity with the
radiation therapy dose-fractionation used in PLUMMB (4).
At 12 months after radiation therapy only 4.5% have
ongoing grade 3 toxicity in the urinary or bowel domains.
Cummulative incidence of local progression at 12 months
is 7% (4).The prominent urinary toxicity encountered in the first 5
patients of this study is far greater than we would have
anticipated with this schedule and met the pre-determined
criterion for declaring maximum tolerated dose (MTD) in
this setting. The authors believe that the relative paucity of
data regarding hypofractionated radiation therapy com-
bined with ICB in pelvic malignancy means that it would
be prudent to amend the study at this point.
Pembrolizumab itself does not appear to have a dose-
response curve and no maximally tolerated dose was noted
in the initial trials of this agent (8). Therefore, in retrospect,
dose-escalation of radiation therapy (rather than of pem-
brolizumab) may have been a better design. At the time, we
were reluctant to reduce the dose of radiation therapy, an
effective and well tolerated regimen, for an uncertain
benefit of adding pembrolizumab. Such a dose-reduced
design would also mandate recruiting only metastatic pa-
tients since, for patients with locally-advanced disease,
radiation therapy to 36 Gy in 6 fractions controls disease
for the patient’s lifespan (4), effectively rendering dose
reduction unethical.
In light of these findings, we will amend the eligibility to
focus on patients with symptomatic metastatic disease and
reduce the dose of radiation therapy to 24 Gy in 4 fractions
(6 Gy per fraction) and, if well tolerated, escalate to 30 Gy
in 5 fractions, followed by an expansion phase. If 24 Gy in
4 fractions is not well tolerated, we will de-escalate the
dose per fraction.
Conclusions
We advise caution to those combining radiation therapy and
ICB, particularly when radiation therapy is given with a
high dose hypofractionated schedule for pelvic tumours.
The PLUMMB trial met the protocol-defined definition
of dose-limiting toxicity and will be amended to reduce
radiation therapy dose.
References
1. Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint
blockade immunotherapy: Radiosensitisation and potential mecha-
nisms of synergy. Lancet Oncol 2015;16:e498-e509.
2. Koller KM, Mackley HB, Liu J, et al. Improved survival and complete
response rates in patients with advanced melanoma treated with
concurrent ipilimumab and radiotherapy versus ipilimumab alone.
Cancer Biol Ther 2017;18:36-42.
3. Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radio-
therapy and the clinical activity and toxicity of pembrolizumab in
the treatment of non-small-cell lung cancer: A secondary analysis
of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017;18:895-
903.
4. Hafeez S, McDonald F, Lalondrelle S, et al. Clinical outcomes of
image guided adaptive hypofractionated weekly radiation therapy for
bladder cancer in patients unsuitable for radical treatment. Int J Radiat
Oncol Biol Phys 2017;98:115-122.
5. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance
to fractionated radiotherapy can be overcome by concurrent PD-L1
blockade. Cancer Res 2014;74:5458-5468.
Volume 101  Number 5  2018 The benefits of combining radiation and immune checkpoint blockades 11716. McDonald F, Lalondrelle S, Taylor H, et al. Clinical imple-
mentation of adaptive hypofractionated bladder radiotherapy for
improvement in normal tissue irradiation. Clin Oncol (R Coll
Radiol) 2013;25:549-556.
7. Aboudaram A, Modesto A, Chaltiel L, et al. Concurrent radio-
therapy for patients with metastatic melanoma and receivinganti-programmed-death 1 therapy. Melanoma Res 2017;27:485-
491.
8. Patnaik A, Kang SP, Rasco D, et al. Phase I study of pem-
brolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in pa-
tients with advanced solid tumors. Clin Cancer Res 2015;21:4286-
4293.
